Vivos Therapeutics Insider Buys Spark Mild Optimism Amid Sharp Stock Slide

Insider Buying Spurs Questions About Vivos’ Near‑Term Outlook The latest Form 4 filing shows Principal Accounting Officer Amman Bradford K. purchased 250,000 shares of Vivos Therapeutics at $0.41 per share on July 31, 2026. The deal increased her holdings to roughly 250,080 shares—an incremental but noteworthy stake given the company’s market cap of just $5.57 million. For a company that has struggled to maintain a positive earnings trajectory (P/E ratio –0.15) and is trading near its 52‑week low, any insider purchase invites scrutiny from investors.

A Mixed Message From the Current Transaction While the purchase itself does not alter the overall ownership structure dramatically, it comes at a time when Vivos’ share price has been sliding almost 8 % over the last week and 37 % over the month. The transaction’s price of $0.41 is only slightly above the current market level ($0.2652), suggesting a modest bullish view rather than a large‑scale confidence boost. Coupled with the 26.95 % buzz on social media, the deal has sparked moderate discussion but no clear consensus on a turnaround.

Broader Insider Activity Signals Strategic Moves The broader insider landscape is dominated by Michael Skaff’s aggressive buying spree in Series A convertible preferred stock and warrants earlier this year, totaling more than 2.7 million shares at $0.58 each. These purchases indicate a long‑term stake in the company’s equity and a willingness to invest in convertible instruments that could pay off if the company’s valuation improves. However, the concentration of insider buying in preferred stock—rather than common shares—suggests a hedged approach, potentially to limit dilution risk while maintaining upside exposure.

Implications for Investors For current shareholders, the incremental common‑share purchase by a senior officer may signal confidence in Vivos’ short‑term prospects, but it does little to offset the company’s steep decline in valuation and earnings. The continued insider buying of convertible preferred shares could be interpreted as a bet on a future liquidity event or a significant valuation increase. Nonetheless, potential investors should weigh the company’s high risk profile, the lack of a positive earnings track record, and the fact that the majority of insider activity is concentrated in the hands of a single individual (Skaff).

In sum, the latest insider transaction adds a modest layer of optimism, but it is dwarfed by broader market concerns. Investors looking to add Vivos should monitor upcoming clinical milestones and any changes in the company’s capital structure before committing capital.